Antileishmanial patents antileishmanial current drugs and relevant patents

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 1, 2011, Pages 1-26

  Monzote, Lianet ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Antiparasitic; Drug; Leishmania; Patents

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ARTEMISININ; AZITHROMYCIN; GENTAMICIN; MEGLUMINE ANTIMONATE; MILTEFOSINE; NATURAL PRODUCT; PAROMOMYCIN; PENTAMIDINE; SAPONIN DERIVATIVE; STIBOGLUCONATE SODIUM;

ARTICLE; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PATENT; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG DISCOVERY; HUMANS; LEISHMANIASIS; PATENTS AS TOPIC;

EID: 79551624346     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111794407868     Document Type: Article

References (68)

1. Handman E. Cell biology of Leishmania. Adv Parasitol 1999; 44: 1-39.
2. Asford RW. The leishmaniasis as model zoonoses. Ann Trop Med Parasitol 1997; 91: 693-701.
3. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: Current treatment and prospect for new drugs and vaccines. Curr Med Chem 2009; 16: 599-614.
4. Pink R, Hudson A, Mouries MA, Bendig M. Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 2005; 4: 727-40.
5. Cowman AF, Crabb BS. Functional genomics: Identifying drug targets for parasitic diseases. Trends Parasitol 2003; 19: 538-43.
6. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: Past, present and future. Curr Med Chem 2010; 14: 1153-69.
7. Sereno D, Cordeiro A, Mathieu-Daude F, Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 2007; 56: 3-7.
8. Ritting MG, Bogdan C. Leishmania host-cell interaction: complexities and alternative views. Parasitol Today 2000; 16: 292-7.
9. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-18.
10. Murray HW, Berman JD, Davies CR, Saraiva NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
11. Herwaldt BL. Leishmaniasis. Lancet 1999; 345: 1191-9.
12. Berman J. Recent developments in leishmaniasis: Epidemiology, diagnosis and treatment. Curr Infect Dis Report 2010; 7: 33-8.
13. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-8.
14. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18: 83-90.
15. Santos DO, Countinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 2008; 103: 1-10.
16. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16: 417-25.
17. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis Am J Trop Med Hyg 2005; 72: 133-7.
18. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Invest Drugs 2008; 17: 787-94.
19. Berman JD. Development of miltefosine for the leishmaniasis. Mini-Rev Med Chem 2006; 6: 145-51.
20. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005; 73: 272-5.
21. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 1999; 43: 2910-4.
22. Alrajhi AA, Ibrahim EA, Devol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-5.
23. Koutinas AF, Saridomichelakis MN, Mylonakis ME, Leontides L, Polizopoulou Z, Billinis C, et al. A randomised, blinded, placebocontrolled clinical trial with allopurinol in canine leishmaniasis. Vet Parasitol 2001; 98: 247-61.
24. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8- aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65: 685-9.
25. Murray HW, Brooks EB, Decchio JL, Hemzel FP. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agent Chemother 2003; 47: 2513-7.
26. Piñero JE, Jiménez IA, Valladares B, Ravelo AG. Advances in leishmaniasis chemotherapy and new relevant patents. Expert Opin Ther Pat 2004; 14: 1113-23.
27. Monzote L. A review of anti-parasitic patents (1988-2008). Recent Pat Anti-Infect Drug Discov 2008; 3: 177-91.
28. Maltezou HC. Visceral leishmaniasis: Advances in treatment. Recent Pat Antiinfect Drug Discov 2008; 3: 192-8.
29. Na-Bangchang K, Karbwang J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam Clin Pharmacol 2009; 23: 387-409.
30. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006; 123: 345-52.
31. Steck, E.A., Alving, C.R. Liposome carriers in chemotherapy of leishmaniasis. US4186183 (1980).
32. Eibl, H.J., Wieland-berghausen, S.C., Steffan, J. Formulations containing alkylphosphocholines using novel negative charger carriers. US20080090781 (2008).
33. Balaña-Fouce R, Requera RM, Cubría JC, Ordóñez D. The pharmacology of leishmaniasis. Gen Pharmacol 1998; 30: 435-43.
34. Tekwani BL, Walker LA. 8-Aminoquinolines: Future role as antiprotozoal drugs. Curr Opin Infect Dis 2006; 19: 623-31.
35. Steck, E.A., Alving, C.R. Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives. US4302459 (1981).
36. Christen P, Veuthey JL. New trends in extraction, identification and quantification of artemisinin and its derivatives. Curr Med Chem 2001; 8: 1827-39.
37. Rosenthal PJ. Antimalarial drug discovery: Old and new approaches. J Exp Biol 2003; 206: 3735-44.
38. Elsohly, M.A., Ross, S.A., Galal, A.M. Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents. US20040072896 (2004).
39. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370-4.
40. Steigbigel N. Macrolides and Clindamycin. In: Mandell G, Bennett J, Dolin R, Eds. 4th ed. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases 1995; 334-46.
41. Abraham, D., Kroleweicki, A.J. Azithromycin as a therapeutic agent for infections with Leishmania parasites. US20020049167 (2002).
42. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob Agents Chemother 1999; 43: 1242-51.
43. Oldfield, E., Song, Y., Zhang, Y., Sanders, J.M. Bisphosphonate compounds and methods. US20070275931 (2007).
44. Fuertes MA, Nguewa PA, Castilla J, Alonso C, Pérez JM. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem 2008; 15: 433-9.
45. Donno, L., Cassinelli, G. Paromomycin or its derivatives or salts thereof in combination with sodium stibogluconate for parenteral treatment of human parasitic diseases. US5470836 (1995).
46. Grogl, M., Fleckenstein, L., Mcgreevy, P., Schuster, B. Antileishmanial composition for topical application. US6284739 (2001).
47. Beverley, S.M., Zhang, K. Compositions and methods for inhibiting protozoan growth. US20100119483 (2010).
48. Morales A, Rodríguez-Borgues JE, García-Mera X, Fernández F, Cordeiro MN. Probing the anticancer activity of nucleoside analogues: A QSAR model approach using an internally consistent training set. J Med Chem 2007; 50: 1537-45.
49. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev 2005; 4: 206-20.
50. Kharazmi, A., Christensen, S.B., Nielsen, S.F. Biologically active 1,3-Bis-aromatic-prop-2-en-1-ones, 1,3-Bis-aromatic-propan-1- ones, and 1,3-Bis-aromatic-prop-2-yn-1-ones. US20030065039 (2003).
51. Nielsen, S.F. Kromann, H., Larsen, M., Hansen, M., Boesen, T. Amino-functional chalcones. US20060052600 (2006).
52. Santos DO, Countinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment--a challenge that remains: a review. Parasitol Res 2008; 103: 1-10.
53. Werbovetz KA. Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis. Curr Med Chem 2000; 7: 835-60.
54. Thompson, S.K., Veber, D.F., Tomaszek, T.A., Tew, D.G. Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily. US20020156018 (2002).
55. Chen, D., Deng, W., Lee, K.C., Lye, P.L., Sun, E.T., Wang, H., Yu, N. Heterocyclic compounds. US20100048300 (2010).
56. Furneaux, R.H., Tyler, P.C., Schramm, V.L. 5H-Pyrrolo [3,2- d]pyrimidine nucleoside metabolism inhibitors. US7109331 (2006).
57. Bonal, F.J., Lopez, L., Vila, L., Molins, A.M. Lacoma, L. Use of 2,4-distributed phenol derivatives as 5-lipoxygenase inhibitors. US5985937 (1999)
58. Mccaffrey, R.P., Wigzell, H.L.R. Compositions for the treatment of parasitic infections. US5663155 (1997)
59. Wiemer, D.F., Hohl, R.J. Geranylgeranyl pyrophosphate synthase inhibitors. US7268124 (2007).
60. Furneaux, R.H., Tyler, P.C., Evans, G.B., Schramm, V.L., Clinch, K. Deazapurine analogs of 1'-aza-l-nucleosides. US20100325986 (2010).
61. Jackson, J.E., Iwu, M.M., Okunji, C.O., Bacchi, C. Talley Jr., J.D. Ayafor, J.F. Antifungal and antiparasitic compounds. US6403576 (2002).
62. Cos P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential natural products: How to develop a stronger in vitro "proof-ofconcept". J Ethnopharmacol 2006; 106: 290-302.
63. Maes, L., Germonprez, N.A.G.,Van Puyvelde, L.E.M., De Kimpe, N.G.M. Ngoc N.T. Antiprotozoal saponins. US6872713 (2005).
64. Costa, L.A., Villarrubia, V.G. Use of Phospholipase A, for the preparation of pharmaceutical and/or cosmetic compositions for prevention and/or local and/or systemic treatment of diseases and conditions caused by intra- and extracellular pathogens expressing membrane phospholipids. US20040166104 (2004).
65. Takemoto, J.Y., Forney, J.R., Healey, M.C., Yang, S., Werbovetz, K.A. Method of controlling protozoan infections using syringomycin-family lipodepsipeptides. US6310037 (2001).
66. Iwu, M.M., Klayman, D.L., Jackson, J.E., Tally, J.D., Andersen, S.L. Alkaloids of Picralima nitida used for treatment of protozoal diseases. US5290553 (1994).
67. Diehl, C., Silvia, C.D. Topical and intravaginal microbicidal ad antiparsitic compositions comprising quassinoids or quassinoidcontaining plant exrtracts. US20080089958 (2008).
68. Wolnerman, J.S. Composition containing monoterpenes for topical oral administration. US20030012743 (2003).